PCSK9
生物
家族性高胆固醇血症
低密度脂蛋白受体
甲基化
DNA甲基化
遗传学
内科学
胆固醇
内分泌学
基因
脂蛋白
医学
基因表达
作者
Elisangela da Silva Rodrigues Marçal,Jéssica Bassani Borges,Gisele Medeiros Bastos,Thiago Dominguez Crespo Hirata,Victor Fernandes de Oliveira,Rodrigo Marques Gonçalves,André Árpád Faludi,João Ítalo Dias França,Daiana Vitor de Oliveira Silva,Vanessa Barbosa Malaquias,André Ducati Luchessi,Vivian Nogueira Silbiger,Marcelo Arruda Nakazone,Tayanne Silva Carmo,Dorotéia Rossi Silva Souza,Marcelo Ferraz Sampaio,Rosário Dominguez Crespo Hirata,Mário Hiroyuki Hirata
出处
期刊:Epigenomics
[Future Medicine]
日期:2024-06-17
卷期号:16 (11-12): 809-820
被引量:1
标识
DOI:10.1080/17501911.2024.2351792
摘要
Aim: Methylation of LDLR, PCSK9 and LDLRAP1 CpG sites was assessed in patients with familial hypercholesterolemia (FH). Methods: DNA methylation of was analyzed by pyrosequencing in 131 FH patients and 23 normolipidemic (NL) subjects.Results: LDLR, PCSK9 and LDLRP1 methylation was similar between FH patients positive (MD) and negative (non-MD) for pathogenic variants in FH-related genes. LDLR and PCSK9 methylation was higher in MD and non-MD groups than NL subjects (p < 0.05). LDLR, PCSK9 and LDLRAP1 methylation profiles were associated with clinical manifestations and cardiovascular events in FH patients (p < 0.05).Conclusion: Differential methylation of LDLR, PCSK9 and LDLRAP1 is associated with hypercholesterolemia and cardiovascular events. This methylation profile maybe useful as a biomarker and contribute to the management of FH.
科研通智能强力驱动
Strongly Powered by AbleSci AI